User:Mr. Ibrahem/Imipenem/cilastatin/relebactam

Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a combination medication and antibiotic used to treat hospital acquired pneumonia, sepsis, urinary tract infections, and intra-abdominal infections. It is given by injection into a vein.

Common side effects include include nausea, diarrhea, headache, fever, inflammation at the site of injection, and increased liver enzymes. Other side effects may include Clostridioides difficile infection, seizures, and anaphylaxis. Imipenem is a penem, cilastatin prevents its breakdown, and relebactam blocks the activity of beta-lactamase.

The combination was approved for medical use in the United States in 2019 and Europe in 2020. In the United Kingdom 25 doses cost the NHS about £3,800 as of 2021. In the United States this amount costs about 7,200 USD.